Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KALV | US
0.39
3.00%
Healthcare
Biotechnology
30/04/2024
30/08/2024
13.39
13.09
13.47
12.68
KalVista Pharmaceuticals Inc. a clinical stage pharmaceutical company discovers develops and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001 a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat which is initiation of the Phase 3 KONFIDENT trial as a potential oral on-demand therapy for HAE attacks; KVD824 an oral product candidate for the treatment of HAE; and Factor XIIa an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.5%1 month
47.4%3 months
53.8%6 months
50.6%-
-
2.79
0.04
0.03
-3.53
76.33
-
-139.63M
576.87M
576.87M
-
-
-
30.70
-68.90
20.52
15.18
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.03
Range1M
3.40
Range3M
4.66
Rel. volume
2.93
Price X volume
9.71M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.73 | 625.38M | -3.89% | n/a | 44.04% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 12.41 | 617.11M | -1.27% | n/a | 0.00% |
ITOS | ITOS | Biotechnology | 16.85 | 615.39M | -0.06% | n/a | 0.83% |
REGENXBIO Inc | RGNX | Biotechnology | 12.22 | 603.95M | 1.83% | n/a | 45.57% |
ANNX | ANNX | Biotechnology | 5.7 | 602.23M | -3.88% | n/a | 8.36% |
UroGen Pharma Ltd | URGN | Biotechnology | 13.91 | 585.81M | -0.64% | n/a | 326.69% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 21.1 | 570.59M | 0.81% | n/a | 11.94% |
PureTech Health plc | PTCHF | Biotechnology | 2.09 | 567.53M | n/a | 29.73% | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 6.7 | 566.98M | 9.30% | n/a | 13.27% |
Pharming Group N.V. | PHAR | Biotechnology | 7.69 | 558.03M | -1.16% | n/a | 63.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.94 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 49.80 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.70 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.84 | -621.78% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 18.53 | 314.66M | -0.70% | 36.33 | 26.79% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 15.53 | 251.70M | 1.70% | 9.96 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.42 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.53 | 0.97 | Cheaper |
Ent. to Revenue | 76.33 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 2.79 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 53.76 | 76.13 | Lower Risk |
Debt to Equity | 0.04 | -2.05 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 576.87M | 4.04B | Emerging |